

Zachariah DeFilipp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6221311/publications.pdf>

Version: 2024-02-01

90
papers

3,135
citations

186265
28
h-index

175258
52
g-index

93
all docs

93
docs citations

93
times ranked

4401
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant. New England Journal of Medicine, 2019, 381, 2043-2050.	27.0	767
2	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019, 134, 860-866.	1.4	178
3	Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Advances, 2018, 2, 745-753.	5.2	167
4	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood, 2021, 138, 2278-2289.	1.4	124
5	Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. Blood, 2018, 132, 2506-2519.	1.4	120
6	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
7	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555.	2.4	75
8	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
9	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
10	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Advances, 2019, 3, 4034-4042.	5.2	63
11	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
12	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
13	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
14	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.8	47
15	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	1.2	45
16	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer, 2018, 124, 816-825.	4.1	44
17	Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e17-e22.	2.0	44
18	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 228-241.	2.0	43

#	ARTICLE	IF	CITATIONS
19	High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. <i>Cancer</i> , 2017, 123, 3073-3079.	4.1	41
20	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
21	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 909-913.	2.0	39
22	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	5.2	38
23	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.4	37
24	Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1741-1747.	2.0	36
25	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
26	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	5.2	36
27	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
28	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
29	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
30	Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial. <i>Cancer</i> , 2020, 126, 1758-1765.	4.1	32
31	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	1.2	29
32	Coping and Modifiable Psychosocial Factors are Associated with Mood and Quality of Life in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2234-2242.	2.0	28
33	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	5.2	27
34	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
35	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	5.2	24
36	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with $\hat{\pm}$ -1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	5.2	24

#	ARTICLE	IF	CITATIONS
37	Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. <i>Oncologist</i> , 2022, 27, 685-693.	3.7	23
38	Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. <i>Oncologist</i> , 2018, 23, 624-630.	3.7	21
39	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
40	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. <i>Blood</i> , 2019, 134, 211-215.	1.4	18
41	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
42	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16
43	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 25, e145-e154.	2.0	16
44	Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2134-2140.	2.0	15
45	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	2.4	15
46	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
47	High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 884-888.	0.4	14
48	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
49	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
50	T Cell Clonal Dynamics Determined by High-Resolution TCR- \hat{I}^2 Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1567-1574.	2.0	11
51	How I treat with maintenance therapy after allogeneicÂHCT. <i>Blood</i> , 2023, 141, 39-48.	1.4	11
52	Sharing and caring: The impact of social support on quality of life and health outcomes in hematopoietic stem cell transplantation. <i>Cancer</i> , 2021, 127, 1260-1265.	4.1	10
53	Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 479.e1-479.e7.	1.2	10
54	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. <i>Blood</i> , 2022, 139, 3583-3593.	1.4	10
56	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
57	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	5.2	9
58	Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1836-1840.	2.0	8
59	ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e86-e88.	2.0	8
60	Distress in a Pandemic - The Association of the Coronavirus Disease-2019 (COVID-19) Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation (HSCT). <i>Transplantation and Cellular Therapy</i> , 2021, , .	1.2	8
61	Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , 2015, 126, 1938-1938.	1.4	8
62	Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment. <i>Blood</i> , 2021, 138, 263-263.	1.4	8
63	Management of Advanced-Phase Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 173-181.	2.3	7
64	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
65	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. <i>Bone Marrow Transplantation</i> , 2020, 55, 758-762.	2.4	7
66	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
67	Association Between Baseline Patient-Reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 496.e1-496.e5.	1.2	7
68	A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e305-e308.	2.0	6
69	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
70	Ruxolitinib resistance or intolerance in steroidâ€‘refractory acute graftâ€‘versus â€‘host disease â€‘ a realâ€‘world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432.	2.5	6
71	Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2319-2321.	2.4	5
72	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5

#	ARTICLE	IF	CITATIONS
73	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 335.e1-335.e17.	1.2	5
74	Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplantation, 2021, 56, 983-985.	2.4	4
75	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplantation, 2020, 55, 804-810.	2.4	3
76	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplantation and Cellular Therapy, 2022, 28, 712.e1-712.e8.	1.2	3
77	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplantation, 2020, 55, 1178-1180.	2.4	2
78	Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. Oncologist, 2021, 26, e2082-e2085.	3.7	2
79	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018, 132, 1015-1015.	1.4	2
80	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation, 2022, 57, 1150-1163.	2.4	2
81	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	2.4	1
82	A Heart Murmur Is Discovered on an Oncology Ward: Extramedullary Acute Myeloid Leukemia. American Journal of Medicine, 2020, 133, e457-e459.	1.5	1
83	Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. Blood, 2019, 134, 3275-3275.	1.4	1
84	Safety and efficacy of autologous stem cell transplantation in lymphoma patients in their 70s.. Journal of Clinical Oncology, 2017, 35, e19003-e19003.	1.6	1
85	Case 20-2022: A 25-Year-Old Man with Vision Changes. New England Journal of Medicine, 2022, 386, 2508-2516.	27.0	1
86	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Leukemia Research, 2021, 109, 106625.	0.8	0
87	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clinical Hematology International, 2019, 1, 201-204.	1.7	0
88	Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases. Blood, 2019, 134, 1978-1978.	1.4	0
89	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. Blood, 2019, 134, 367-367.	1.4	0
90	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 2-3.	1.4	0